New pill HDM2006 tested in patients with advanced cancers

NCT ID NCT07377591

Recruiting now Disease control Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests an experimental oral drug called HDM2006 in 48 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors. Participants take the drug once daily after a meal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HDM2006 (an experimental oral drug)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early, first-in-human Phase 1 trial with only 48 participants. The drug may not be effective or could have significant side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.